Heart Failure Pipeline Report: In-Depth Analysis Into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Heart Failure pipeline constitutes 75+ key companies continuously working towards developing 90+ Heart Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Heart Failure Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.


Some of the key takeaways from the Heart Failure Pipeline Report:

Companies across the globe are diligently working toward developing novel Heart Failure treatment therapies with a considerable amount of success over the years. 
Heart Failure companies working in the treatment market are Rivus Pharmaceutical, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, and others, are developing therapies for the Heart Failure treatment 
Emerging Heart Failure therapies such as – HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, GSK3884464, LY 3461767, JK07, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, and others are expected to have a significant impact on the Heart Failure market in the coming years.  
In February 2023, Mesoblast Limited announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the Journal of the American College of Cardiology (JACC)
In February 2022 Omecamtiv Mecarbil, a selective cardiac myosin activator that is beneficial in enhancing contractility related to heart failure, had its NDA approved by the FDA. Semaglutide, tirzepatide, cimlanod, CardiAMP cell therapy, Revascor (Rexlemestrocel-L), Furoscix infusor, and others are clinical trial medications for CHF. It is anticipated that the approval and subsequent release of such medications will accelerate the expansion of the market
In June 2019, The Food and Drug Administration (FDA) granted Orphan Drug designation to Revascor (rexlemestrocel-L; Mesoblast), a potential therapy for the prevention of post-implantation mucosal bleedingin end-stage chronic heart failure patients who require a left ventricular assist device (LVAD)


Heart Failure Overview

Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function.


Get a Free Sample PDF Report to know more about Heart Failure Pipeline Therapeutic Assessment-



Emerging Heart Failure Drugs Under Different Phases of Clinical Development Include:

HU 6: Rivus Pharmaceutical
PL 3994: Palatin Technologies
AZD9977: AstraZeneca
Rexlemestrocel-L: Mesoblast
Finerenone: Bayer
Tirzepatide: Eli Lilly and Company
GSK3884464: GlaxoSmithKline
LY 3461767: Eli Lilly and Company
JK07: Salubris Biotherapeutics
HS-001: Heartseed Inc
SRD-001: Sardocor Corp.
hiPSC-CM therapy: Help Therapeutics
Mavacamten: Bristol Myers Squibb


Route of Administration

Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 



Molecule Type

Products have been categorized under various Molecule types, such as

Small molecule


Heart Failure Pipeline Therapeutics Assessment

Heart Failure Assessment by Product Type
Heart Failure By Stage and Product Type
Heart Failure Assessment by Route of Administration
Heart Failure By Stage and Route of Administration
Heart Failure Assessment by Molecule Type
Heart Failure by Stage and Molecule Type


DelveInsight’s Heart Failure Report covers around 90+ products under different phases of clinical development like-

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration


Further Heart Failure product details are provided in the report. Download the Heart Failure pipeline report to learn more about the emerging Heart Failure therapies


Some of the key companies in the Heart Failure Therapeutics Market include:

Key companies developing therapies for Heart Failure are – Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim International GmbH, Pfizer, Inc., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Novo Nordisk A/S, and others.


Heart Failure Pipeline Analysis:

The Heart Failure pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
Heart Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Heart Failure drugs and therapies


Heart Failure Pipeline Market Drivers

Biomarkers helps in understanding the complexity of heart failure, recent advancements in research and development, rising geriatric population are some of the important factors that are fueling the Heart Failure Market.


Heart Failure Pipeline Market Barriers

However, lack of therapies for HFpEF and acute heart failure, high annual cost, long time duration to measure the Clinical trial endpoints and other factors are creating obstacles in the Heart Failure Market growth.


Scope of Heart Failure Pipeline Drug Insight    

Coverage: Global
Key Heart Failure Companies: Rivus Pharmaceutical, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, and others
Key Heart Failure Therapies: HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, GSK3884464, LY 3461767, JK07, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, and others
Heart Failure Therapeutic Assessment: Heart Failure current marketed and Heart Failure emerging therapies
Heart Failure Market Dynamics: Heart Failure market drivers and Heart Failure market barriers 


Request for Sample PDF Report for Heart Failure Pipeline Assessment and clinical trials


Table of Contents


Heart Failure Report Introduction


Heart Failure Executive Summary


Heart Failure Overview


Heart Failure- Analytical Perspective In-depth Commercial Assessment


Heart Failure Pipeline Therapeutics


Heart Failure Late Stage Products (Phase II/III)


Heart Failure Mid Stage Products (Phase II)


Heart Failure Early Stage Products (Phase I)


Heart Failure Preclinical Stage Products


Heart Failure Therapeutics Assessment


Heart Failure Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Heart Failure Key Companies


Heart Failure Key Products


Heart Failure Unmet Needs


Heart Failure Market Drivers and Barriers


Heart Failure Future Perspectives and Conclusion


Heart Failure Analyst Views




About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: